The Readout Loud
A podcast by STAT - Thursdays
Categories:
336 Episodes
-
254: The legal battle over abortion, an FDA 'bully pulpit' and Moderna's future
Published: 4/13/2023 -
253: Illumina’s boardroom intrigue, the next big Alzheimer’s readout, & J&J’s creative lawyers
Published: 4/6/2023 -
252: Biotech's monkey shortage, the broken generics market, & conference cancel culture
Published: 3/30/2023 -
251: Bancel v. Bernie, Sarepta's FDA runaround, & Regeneron's ever-growing blockbuster
Published: 3/23/2023 -
250: SVB's long biotech shadow, pushy AI algorithms, & Icahn v. Illumina
Published: 3/16/2023 -
249: Robert Califf on how drugs get approved, plus the nascent revolution in obesity
Published: 3/9/2023 -
248: The next CRISPR fight, cheaper insulin, & an FDA shuffle
Published: 3/2/2023 -
247: Vertex vs. insurers, Moderna's future, & biotech's long winter
Published: 2/23/2023 -
246: Vas Narasimhan on the future of pharma, plus Moderna’s promise & a biotech presidential bid
Published: 2/16/2023 -
245: The return of bird flu and the effects of pandemic fatigue
Published: 2/9/2023 -
244: Pharma blockbusters, pandemic policy, & legal chicanery
Published: 2/2/2023 -
243: George Scangos' retirement, annual Covid vaccines, an Alzheimer's drug rejection
Published: 1/26/2023 -
242: How blockbusters get made, new vaccines for RSV, and mRNA's Q score
Published: 1/19/2023 -
241: #JPM23 in review, the year ahead, & the merits of Miami
Published: 1/12/2023 -
240: #JPM23, the future of Alzheimer's, & rising Covid variants
Published: 1/5/2023 -
239: 2022 in review, CEO indictments, & the year ahead
Published: 12/22/2022 -
238: Leaky health data, ASH22, & what it takes to get booed by your peers
Published: 12/15/2022 -
237: The 'electric vehicles' of pharma, Illumina's boondoggle, & a Theranos sentencing
Published: 12/8/2022 -
236: Wither PhRMA, Alzheimer's treatment data revealed, and the first fecal microbiome drug approval
Published: 12/1/2022 -
235: LIVE from the STAT Summit
Published: 11/17/2022
STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.